These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37109590)

  • 1. Impact of Baseline Clinical Variables on SGLT2i's Antiproteinuric Effect in Diabetic Kidney Disease.
    Capelli I; Ribichini D; Provenzano M; Vetrano D; Aiello V; Cianciolo G; Vicennati V; Tomassetti A; Moschione G; Berti S; Pagotto U; La Manna G
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics.
    Provenzano M; Chiodini P; Minutolo R; Zoccali C; Bellizzi V; Conte G; Locatelli F; Tripepi G; Del Vecchio L; Mallamaci F; Di Micco L; Russo D; Heerspink HJL; De Nicola L
    Nephrol Dial Transplant; 2020 Jan; 35(1):138-147. PubMed ID: 30053127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
    Ma C; Li X; Li W; Li Y; Shui F; Zhu P
    Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
    Rossing P; Anker SD; Filippatos G; Pitt B; Ruilope LM; Birkenfeld AL; McGill JB; Rosas SE; Joseph A; Gebel M; Roberts L; Scheerer MF; Bakris GL; Agarwal R;
    Diabetes Care; 2022 Dec; 45(12):2991-2998. PubMed ID: 35972218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the natural history of diabetic kidney disease (DKD).
    Altemtam N; Russell J; El Nahas M
    Nephrol Dial Transplant; 2012 May; 27(5):1847-54. PubMed ID: 22058177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease.
    Sugiyama S; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T; Jinnouchi H
    J Clin Med Res; 2020 Nov; 12(11):724-733. PubMed ID: 33224374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
    Nagasu H; Yano Y; Kanegae H; Heerspink HJL; Nangaku M; Hirakawa Y; Sugawara Y; Nakagawa N; Tani Y; Wada J; Sugiyama H; Tsuruya K; Nakano T; Maruyama S; Wada T; Yamagata K; Narita I; Tamura K; Yanagita M; Terada Y; Shigematsu T; Sofue T; Ito T; Okada H; Nakashima N; Kataoka H; Ohe K; Okada M; Itano S; Nishiyama A; Kanda E; Ueki K; Kashihara N
    Diabetes Care; 2021 Nov; 44(11):2542-2551. PubMed ID: 34593566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.
    Yano K; Seko Y; Takahashi A; Okishio S; Kataoka S; Takemura M; Okuda K; Mizuno N; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Okanoue T; Itoh Y
    Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32041289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.
    Shimada K; Kanasaki K; Kato M; Ogura Y; Takagaki Y; Monno I; Hirai T; Kitada M; Koya D
    J Diabetes Investig; 2022 Jun; 13(6):955-964. PubMed ID: 35098679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i).
    Kim SH; Chang TI; Mahaffey KW
    Cardiol Ther; 2020 Dec; 9(2):219-225. PubMed ID: 32661684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
    Othman M; Kawar B; El Nahas AM
    Nephron Clin Pract; 2009; 113(1):c16-23. PubMed ID: 19590231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
    Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
    J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.